Review article · 2025 · Open access

Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer

Edgar Pérez‐Herrero, Alberto Fernández‐Medarde, Juan M. Irache

Acta Pharmaceutica Sinica B, 16(4), 1883–1913 · Published 3 December 2025 · DOI 10.1016/j.apsb.2025.11.035

Open full textCite this paper

In brief

“Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer” is a 2025 review article by Edgar Pérez‐Herrero and 2 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 19 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.

Citations
19
Most cited in
2026 (19)
Field-weighted impact
0.72
References
396
Authors
3

Abstract

Proteins have emerged as highly promising biomaterials for the design of drug-loaded nanocarriers due to their biocompatibility, biodegradability and reduced immunogenicity. Among them, albumin stands out as the most widely used due to its unique physicochemical and biological properties, high affinity to important cell surface receptors, structural stability, long circulation time and intrinsic binding capacities. This review provides an overview of the advantages and limitations of the main proteins that have been proposed as biomaterials for nanoparticle fabrication, with a specific focus on albumin-based systems. It explores the physicochemical characteristics of these nanosystems, receptor binding affinity and functionalization strategies for both passive and active tumor targeting. The main synthesis methods and functionalization strategies are discussed, highlighting their relevance in cancer therapy. Their clinical relevance is stressed by the US Food and Drug Administration (FDA)-approved formulations and the additional albumin-bound drugs in ongoing trials. Despite promising preclinical data and numerous active targeting approaches reported, clinical translation remains limited. This review provides the necessary information to develop improved strategies and cover the gap between preclinical research and clinical application and outlines future perspectives for enhancing the therapeutic efficacy and specificity of albumin-based drug delivery nanosystems in oncology.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Pérez‐Herrero, E., Fernández‐Medarde, A., & Irache, J. M. (2025). Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer. Acta Pharmaceutica Sinica B, 16(4), 1883–1913. https://doi.org/10.1016/j.apsb.2025.11.035

MLA 9

Pérez‐Herrero, Edgar, et al. “Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer.” Acta Pharmaceutica Sinica B, vol. 16, no. 4, 2025, pp. 1883–1913. https://doi.org/10.1016/j.apsb.2025.11.035.

Chicago

Pérez‐Herrero, Edgar, Alberto Fernández‐Medarde, and Juan M. Irache. 2025. “Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer.” Acta Pharmaceutica Sinica B 16 (4): 1883–1913. https://doi.org/10.1016/j.apsb.2025.11.035.

Harvard

Pérez‐Herrero, E., Fernández‐Medarde, A. and Irache, J. M. (2025) ‘Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer’, Acta Pharmaceutica Sinica B, 16(4), pp. 1883–1913. doi:10.1016/j.apsb.2025.11.035.

IEEE

E. Pérez‐Herrero, A. Fernández‐Medarde, and J. M. Irache, “Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer,” Acta Pharmaceutica Sinica B, vol. 16, no. 4, pp. 1883–1913, 2025, doi: 10.1016/j.apsb.2025.11.035.

BibTeX

@article{perezherrero2025albumin,
  title     = {{Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer}},
  author    = {Pérez‐Herrero, Edgar and Fernández‐Medarde, Alberto and Irache, Juan M.},
  journal   = {Acta Pharmaceutica Sinica B},
  year      = {2025},
  volume    = {16},
  number    = {4},
  pages     = {1883--1913},
  doi       = {10.1016/j.apsb.2025.11.035},
  url       = {https://doi.org/10.1016/j.apsb.2025.11.035}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery

  • protein-based drug delivery
  • nanoparticle synthesis
  • active tumor targeting
  • passive targeting
  • receptor binding affinity
  • cancer therapy
  • clinical translation

Work with this paper

Most-cited papers in Materials Science

All highly cited Materials Science papers

Questions about this paper

How do I cite this paper in APA style?

Pérez‐Herrero, E., Fernández‐Medarde, A., & Irache, J. M. (2025). Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer. Acta Pharmaceutica Sinica B, 16(4), 1883–1913. https://doi.org/10.1016/j.apsb.2025.11.035

How many times has this paper been cited?

19 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the full text from this page.

Who wrote this paper?

Edgar Pérez‐Herrero, Alberto Fernández‐Medarde, Juan M. Irache.

What is the DOI of this paper?

10.1016/j.apsb.2025.11.035, permanently at https://doi.org/10.1016/j.apsb.2025.11.035. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.